Sanofi Share Price Euronext Paris
Stocks
SANNV
FR001400M6Z3
Pharmaceuticals
OTC Markets Traded| Market Cap | 90.47B 101B 83.64B 75.75B 142B 9,603B 143B 1,000B 398B 5,025B 378B 370B 15,953B | P/E 2026 * |
12x | P/E 2027 * | 10.4x |
|---|---|---|---|---|---|
| Enterprise Value | 102B 113B 93.95B 85.09B 159B 10,787B 161B 1,123B 447B 5,645B 425B 416B 17,920B | EV / Sales 2026 * |
2.13x | EV / Sales 2027 * | 1.94x |
| Free-Float |
88.34% | Yield 2026 * |
5.65% | Yield 2027 * | 5.97% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 30/04/2026 | |
| Director of Finance/CFO | 64 | 31/03/2024 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 29/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 27/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 27/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 101B | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,148B | |
| +0.86% | +5.14% | +45.00% | +86.15% | 652B | |
| -0.14% | +0.42% | +25.69% | +105.85% | 505B | |
| +0.33% | +2.27% | +53.99% | +66.18% | 384B | |
| -0.63% | -5.97% | +61.93% | +37.06% | 348B | |
| +2.77% | +3.35% | +35.23% | +57.39% | 294B | |
| +1.65% | 0.00% | +3.34% | +27.03% | 264B | |
| +0.87% | +3.08% | +54.69% | +72.74% | 244B | |
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | |
| Average | +1.74% | +1.39% | +41.33% | +76.68% | 448.57B | |
| Weighted average by Cap. | +2.20% | +1.50% | +45.00% | +89.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.6B 53.05B 44.01B 39.86B 74.46B 5,053B 75.36B 526B 210B 2,644B 199B 195B 8,394B | 50.7B 56.51B 46.88B 42.46B 79.32B 5,382B 80.28B 560B 223B 2,816B 212B 208B 8,941B |
| Net income | 7.69B 8.57B 7.11B 6.44B 12.03B 816B 12.18B 85.01B 33.86B 427B 32.17B 31.49B 1,356B | 9.1B 10.14B 8.41B 7.62B 14.23B 966B 14.41B 101B 40.06B 505B 38.06B 37.25B 1,604B |
| Net Debt | 11.15B 12.43B 10.31B 9.34B 17.45B 1,184B 17.66B 123B 49.11B 620B 46.65B 45.67B 1,967B | 7.68B 8.56B 7.1B 6.43B 12.02B 815B 12.16B 84.92B 33.82B 427B 32.13B 31.45B 1,355B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
